SCHEMBL6603203

SCHEMBL6603203

CCOc1cc(-c2ccc3c(c2)OCO3)nn1CCOc1ccc2cc(Br)ccc2c1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
IDO1 P14902 2/20 0.40
TDO2 P48775 1/20 0.40
KMT2A Q03164 3/20 0.38
RXFP1 Q9HBX9 2/20 0.38
KDM4E B2RXH2 4/20 0.36
NCOR2 Q9Y618 2/20 0.36
MEN1 O00255 2/20 0.36
POLB P06746 2/20 0.36
GAA P10253 1/20 0.36
MC4R P32245 1/20 0.36
PPARG P37231 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 5/20 0.36
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6600812 0.85 S1PR1 (0.35) IDO1TDO2KMT2ARXFP1KDM4E
SCHEMBL6602524 0.84 ADORA1 (0.40) NPC1RAB9AKMT2ARXFP1KDM4E
SCHEMBL6602269 0.83 IDO1 (0.37) IDO1TDO2KMT2ARXFP1KDM4E
SCHEMBL6603578 0.83 RXFP1 (0.36) IDO1TDO2KMT2ARXFP1KDM4E
SCHEMBL6602616 0.82 PTGES (0.35) NPC1RAB9AKMT2ARXFP1KDM4E
SCHEMBL6601651 0.82 RXFP1 (0.36) KMT2ARXFP1KDM4EMEN1NPSR1
SCHEMBL6606013 0.82 RXFP1 (0.37) NPC1RAB9AIDO1TDO2KMT2A
SCHEMBL6603093 0.82 PTGES (0.34) KMT2ARXFP1KDM4EMEN1GAA
SCHEMBL6613466 0.81 TP53 (0.43) KMT2ARXFP1KDM4EMEN1POLB
SCHEMBL6607341 0.80 CNR2 (0.36) RAB9AKMT2ARXFP1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 NPC1 2642/4885RAB9A 2533/4885IDO1 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.